- Rediscovering a lost chemotherapeutic
Race Oncology is currently focused on the development of bisantrene, which had been the subject of over 40 clinical trials in the 1980s and 1990s as part of Lederle’s search for a safer anthracycline (a widely used class of chemotherapeutics that is associated with cardiotoxicity). Despite positive efficacy data across a variety of cancers, especially AML (it was even approved for the treatment of AML in France in 1990 but never commercialised), development stopped after Lederle was sold to Wyeth and then Wyeth was sold to Pfizer. Race will be developing bisantrene for relapsed/refractory AML and expects to initiate a pivotal trial for approval in the US around the end of 2018.Race Oncolology is principally engaged in developing, manufacturing and marketing speciality pharmaceuticals in the cancer field.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.